US equities |
GOOGL $283.82 ▼-12.64% GOOG $282.32 ▼-12.29% MU $934.27 ▼-4.98% MSFT $530.14 ▼-0.16% AMZN $243.79 ▼-4.25% META $624.52 ▲+1.96% NVDA $213.66 ▼-0.80% AAPL $348.91 ▲+1.48%
FinancialContent

Articles published by Dyadic International, Inc.

< Previous 1 2 3 Next >
News headline image
Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Dyadic to Report Q2 2026 Financial Results and Host Conference Call on Wednesday August 12, 2026
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Dyadic Announces Continued Listing on the Nasdaq Capital Market
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Dyadic Expands IP Protection and Business Development Activities in Japan
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutrition, and Bioindustrial Markets
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic’s Recombinant Growth Factors and Media Proteins
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Dyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Dyadic Applied BioSolutions Announces Milestone Achievements and Recent Company Developments
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Dyadic to Present at Investor Conferences and BPI East
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
UPDATE: Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Dyadic International, Inc. Announces Proposed Public Offering of Common Stock
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
News headline image
Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
< Previous 1 2 3 Next >